Academic Journal

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

التفاصيل البيبلوغرافية
العنوان: Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes
المؤلفون: Meister, Michael T, Groot Koerkamp, Marian J A, de Souza, Terezinha, Breunis, Willemijn B, Frazer-Mendelewska, Ewa, Brok, Mariël, DeMartino, Jeff, Manders, Freek, Calandrini, Camilla, Kerstens, Hinri H D, Janse, Alex, Dolman, M Emmy M, Eising, Selma, Langenberg, Karin P S, van Tuil, Marc, Knops, Rutger R G, van Scheltinga, Sheila Terwisscha, Hiemcke-Jiwa, Laura S, Flucke, Uta, Merks, Johannes H M, van Noesel, Max M, Tops, Bastiaan B J, Hehir-Kwa, Jayne Y, Kemmeren, Patrick, Molenaar, Jan J, van de Wetering, Marc, van Boxtel, Ruben, Drost, Jarno, Holstege, Frank C P
المصدر: Meister, Michael T; Groot Koerkamp, Marian J A; de Souza, Terezinha; Breunis, Willemijn B; Frazer-Mendelewska, Ewa; Brok, Mariël; DeMartino, Jeff; Manders, Freek; Calandrini, Camilla; Kerstens, Hinri H D; Janse, Alex; Dolman, M Emmy M; Eising, Selma; Langenberg, Karin P S; van Tuil, Marc; Knops, Rutger R G; van Scheltinga, Sheila Terwisscha; Hiemcke-Jiwa, Laura S; Flucke, Uta; Merks, Johannes H M; van Noesel, Max M; Tops, Bastiaan B J; Hehir-Kwa, Jayne Y; Kemmeren, Patrick; Molenaar, Jan J; van de Wetering, Marc; van Boxtel, Ruben; Drost, Jarno; Holstege, Frank C P (2022). Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. EMBO Molecular ....
بيانات النشر: Wiley Open Access
سنة النشر: 2022
المجموعة: University of Zurich (UZH): ZORA (Zurich Open Repository and Archive
مصطلحات موضوعية: Medical Clinic, 610 Medicine & health
الوصف: Rhabdomyosarcomas (RMS) are mesenchyme-derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high-risk patients. Discovery of new therapies would benefit from additional preclinical models. Here, we describe the generation of a collection of 19 pediatric RMS tumor organoid (tumoroid) models (success rate of 41%) comprising all major subtypes. For aggressive tumors, tumoroid models can often be established within 4-8 weeks, indicating the feasibility of personalized drug screening. Molecular, genetic, and histological characterization show that the models closely resemble the original tumors, with genetic stability over extended culture periods of up to 6 months. Importantly, drug screening reflects established sensitivities and the models can be modified by CRISPR/Cas9 with TP53 knockout in an embryonal RMS model resulting in replicative stress drug sensitivity. Tumors of mesenchymal origin can therefore be used to generate organoid models, relevant for a variety of preclinical and clinical research questions.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 1757-4676
Relation: https://www.zora.uzh.ch/id/eprint/224553/1/EMBO_Mol_Med___2022___Meister___Mesenchymal_tumor_organoid_models_recapitulate_rhabdomyosarcoma_subtypes__1_.pdf; info:pmid/35916583; urn:issn:1757-4676
DOI: 10.15252/emmm.202216001
الاتاحة: https://www.zora.uzh.ch/id/eprint/224553/
https://www.zora.uzh.ch/id/eprint/224553/1/EMBO_Mol_Med___2022___Meister___Mesenchymal_tumor_organoid_models_recapitulate_rhabdomyosarcoma_subtypes__1_.pdf
https://doi.org/10.15252/emmm.202216001
Rights: info:eu-repo/semantics/openAccess ; Creative Commons: Attribution 4.0 International (CC BY 4.0) ; http://creativecommons.org/licenses/by/4.0/
رقم الانضمام: edsbas.6B5A6599
قاعدة البيانات: BASE
الوصف
تدمد:17574676
DOI:10.15252/emmm.202216001